6-methyl-5-nitro-1H-pyridin-2-one | CAS:28489-45-4

We serve 6-methyl-5-nitro-1H-pyridin-2-one CAS:28489-45-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
6-methyl-5-nitro-1H-pyridin-2-one

Chemical Name:6-methyl-5-nitro-1H-pyridin-2-one
CAS.NO:28489-45-4
Synonyms:6-methyl-5-nitro-1H-pyridin-2-one
6-Hydroxy-3-nitro-2-picoline
6-hydroxy-2-methyl-3-nitropyridine
2-Hydroxy-5-nitro-6-methylpyridine
6-Methyl-5-nitropyridin-2-ol
2-Hydroxy-5-nitro-6-methylpyridin
Molecular Formula:C6H6N2O3
Molecular Weight:154.12300
 
Physical and Chemical Properties:
Density:1.36
Melting point:230-232ºC
Boiling point:326.4ºC
Flash point:151.2ºC
 
Specification:
Appearance:Light brown to brown crystalline powder
Assay:≥98.0%
Moisture:≤0.5%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 6-methyl-5-nitro-1H-pyridin-2-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Hydroxy-5-nitro-6-methylpyridin physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Hydroxy-5-nitro-6-methylpyridine Use and application,2-Hydroxy-5-nitro-6-methylpyridine technical grade,usp/ep/jp grade.


Related News: All of China’s provinces and territories have now been touched by the outbreak.DL-Butyrine manufacturer Further research on Oligomannate’s pharmacological mechanism and long-term safety and effectiveness is required, according to the NMPA statement.(3R,4S,5R,6R)-3,4,5-tris(trimethylsilyloxy)-6-(trimethylsilyloxymethyl)oxan-2-one supplier Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.4-Bromo-2-Chlorobenzoic Acid vendor Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.